Aquinox Pharmaceuticals (NASDAQ:AQXP) Trading 7.1% Higher

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) traded up 7.1% during mid-day trading on Thursday . The stock traded as high as $2.91 and last traded at $2.86, 175,509 shares traded hands during trading. An increase of 157% from the average session volume of 68,395 shares. The stock had previously closed at $2.67.

The business’s 50-day moving average is $2.46.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Tuesday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter.

A number of hedge funds and other institutional investors have recently made changes to their positions in AQXP. Acadian Asset Management LLC increased its holdings in shares of Aquinox Pharmaceuticals by 22.1% in the 1st quarter. Acadian Asset Management LLC now owns 603,490 shares of the company’s stock worth $1,627,000 after buying an additional 109,350 shares during the last quarter. Spark Investment Management LLC increased its holdings in shares of Aquinox Pharmaceuticals by 5.6% in the 1st quarter. Spark Investment Management LLC now owns 85,515 shares of the company’s stock worth $230,000 after buying an additional 4,560 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Aquinox Pharmaceuticals by 154.1% in the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock worth $74,000 after buying an additional 20,800 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Aquinox Pharmaceuticals by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 170,483 shares of the company’s stock worth $368,000 after buying an additional 4,280 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Aquinox Pharmaceuticals by 27.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 350,009 shares of the company’s stock worth $756,000 after buying an additional 74,725 shares during the last quarter. Institutional investors own 71.69% of the company’s stock.

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

Featured Article: What is Cost of Capital?

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.